International Scholarly Research Notices

Review Article

Sexually Transmitted Infections and Male Circumcision: A Systematic Review and Meta-Analysis

Table 2

Meta-analysis of circumcision status of adult males and incidence of sexually transmitted infections using Poisson regression.
StudyIntact infections/patient yearsCircumcised infections/patient yearsRelative risk95% confidence interval
GDS    
 Tobian; unadjusted60/279053/27401.11180.7684–1.6086
 Tobian; 6 weeks*60/279053/2423.850.98350.6797–1.4230
Chlamydia    
 Diseker36/34688/11091.30730.8872–1.9267
 Mehta101/209188/2027.51.11280.8362–1.4810
 Mehta; 6 weeks*101/20911875.431.02940.7735–1.3700
 SOB32/1541.7519/1550.51.69380.9601–2.9880
 SOB; 6 weeks*32/1541.7519/1448.271.58200.8968–2.7910
Summary  1.26381.0194–1.5669
Summary; 6 weeks*  1.19730.9648–1.4859
Gonorrhea    
 Diseker36/34683/11091.39030.9402–2.0557
 Mehta74/210270/20651.03850.7490–1.4399
 Mehta; 6 weeks*74/210270/1912.920.96200.6938–1.3339
 SOB91/1541.7589/1550.51.02830.7677–1.3772
 SOB; 6 weeks*91/1541.7589/1448.270.96050.7171–1.2864
Summary  1.10530.9116–1.3402
Summary; 6 weeks*  1.04480.8611–1.2677
GUD    
 Mehta101/195051/19121.94181.3800–2.7191
 Mehta; 6 weeks*101/195051/1753.811.78121.2720–2.4940
 Tobian75/279048/27401.53491.0681–2.2045
 Tobian; 6 weeks*75/279048/2581.921.44601.0065–2.0774
Summary  1.74441.3637–2.2313
Summary; 6 weeks*  1.61951.2660–2.0716
Syphilis    
 Diseker4/3476/11092.13060.5560–7.5504
 Mehta6/19767/1897.50.82300.2766–2.4490
 Mehta; 6 weeks*6/19767/1741.730.75580.2539–2.2481
 Tobian45/428650/41660.87480.5848–1.3087
 Tobian; 6 weeks*45/428650/3925.650.82430.5511–1.2334
Summary  0.92670.6429–1.3359
Summary; 6 weeks*  0.87380.6059–1.2600
HSV    
 Dickson19/223513/15120.98880.4883–2.0019
 Mehta100/1628.586/1493.51.06640.7993–1.4226
 Mehta; 6 weeks*100/1628.586/1379.730.98520.7384–1.3145
 SOB35/100323/9951.50950.8921–2.5546
 SOB; 6 weeks*35/100323/929.391.41000.8332–2.3862
 Tobian153/2906.5114/2888.51.33381.0466–1.6998
 Tobian; 6 weeks*153/2906.5114/2704.811.24890.9800–1.5917
Summary  1.23021.0381–1.4581
Summary; 6 weeks*  1.15060.9709–1.3636
HPV    
 Auvert144/1086.2590/1125.251.51321.1651–1.9650
 Auvert; 6 weeks*144/1086.2590/1051.061.41341.0883–1.8355
 Auvert ADJ†217.50/1086.25193.03/1125.251.06570.8786–1.2924
 Auvert ADJ; 6 weeks*†217.50/1086.25193.03/1051.060.99530.8207–1.2072
 Dickson54/783041/52200.87800.5851–1.3177
 Lajous37/1748/361.04510.4867–2.2441
 Lu7/25.456/243.31.19670.5454–2.6256
 Partridge32/2486132/78400.76450.5196–1.1249
 Tobian80/57442/4661.54641.0644–2.2466
 Tobian; 6 weeks*80/57442/412.231.36790.9416–1.9873
 Tobian ADJ†120.83/57490.08/4661.08890.8289–1.4306
 Tobian ADJ; 6 weeks*†120.83/57490.08/412.230.96330.7333–1.2655
 VanBuskirk45/124142/4121.05300.7530–1.4724
Summary  1.16401.0097–1.3421
Summary; 6 weeks*  1.11840.9696–1.2902
Summary ADJ†  1.01130.8941–1.1439
Summary ADJ; 6 weeks*†  0.95910.8475–1.0852
Any STI    
 Dickson70/299147/12960.95910.6627–1.3879
 Diseker135/356475/11090.88530.7313–1.0718
 Fergusson37/28487/12322.28641.0194–5.1289
 Mattson17/265.527/2350.55830.3043–1.0244
Summary  0.91270.7801–1.0679
Adjusted for a 6-week lead time bias.
Adjusted for sampling bias using data from VanBuskirk et al. [32].